Elmhurst Memorial Hospital- Nancy W. Knowles Cancer Center

Elmhurst, Illinois 60126

0 studies enrolling now · 3 studies all time

What they study most

HER2-Positive Primary Breast Cancer, Non Small Cell Lung Cancer ALK Positive or ROS1 Positive, Pancreatic Cancer Non-resectable, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer — Completed
• Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive — NO_LONGER_AVAILABLE